Stock Scorecard
Stock Summary for eFFECTOR Therapeutics Inc (EFTR) - $0.04 as of 9/7/2024 12:05:32 AM EST
Total Score
7 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for EFTR
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for EFTR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for EFTR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for EFTR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for EFTR
Financial Details for EFTR
Company Overview |
|
|---|---|
| Ticker | EFTR |
| Company Name | eFFECTOR Therapeutics Inc |
| Country | USA |
| Description | N/A |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2024 |
| Next Earnings Date | 11/11/2024 |
Stock Price History |
|
| Last Day Price | 0.04 |
| Last Day Price Updated | 9/7/2024 12:05:32 AM EST |
| Last Day Volume | 15,263 |
| Average Daily Volume | 49,760 |
| 52-Week High | 17.90 |
| 52-Week Low | 0.03 |
| Last Price to 52 Week Low | 33.33% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 34.82 |
| Sector PE | 80.12 |
| 5-Year Average PE | 31.87 |
| Free Cash Flow Ratio | 0.01 |
| Industry Free Cash Flow Ratio | 13.19 |
| Sector Free Cash Flow Ratio | 30.42 |
| Current Ratio Most Recent Quarter | 1.03 |
| Total Cash Per Share | 5.40 |
| Book Value Per Share Most Recent Quarter | 0.21 |
| Price to Book Ratio | 0.23 |
| Industry Price to Book Ratio | 6.02 |
| Sector Price to Book Ratio | 22.15 |
| Price to Sales Ratio Twelve Trailing Months | 69.65 |
| Industry Price to Sales Ratio Twelve Trailing Months | 7.56 |
| Sector Price to Sales Ratio Twelve Trailing Months | 6.66 |
Share Statistics |
|
| Total Shares Outstanding | 4,704,400 |
| Market Capitalization | 188,176 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -57.95% |
| Reported EPS 12 Trailing Months | -12.57 |
| Reported EPS Past Year | -2.16 |
| Reported EPS Prior Year | -3.96 |
| Net Income Twelve Trailing Months | -34,620,000 |
| Net Income Past Year | -35,800,000 |
| Net Income Prior Year | -22,665,000 |
| Quarterly Revenue Growth YOY | 117.00% |
| 5-Year Revenue Growth | 0.07% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 25,400,000 |
| Total Cash Past Year | 4,000,000 |
| Total Cash Prior Year | 26,300,000 |
| Net Cash Position Most Recent Quarter | 5,956,000 |
| Net Cash Position Past Year | -16,000,000 |
| Long Term Debt Past Year | 20,000,000 |
| Long Term Debt Prior Year | 20,000,000 |
| Total Debt Most Recent Quarter | 19,444,000 |
| Equity to Debt Ratio Past Year | -0.41 |
| Equity to Debt Ratio Most Recent Quarter | 0.04 |
| Total Stockholder Equity Past Year | -5,795,000 |
| Total Stockholder Equity Prior Year | 3,896,000 |
| Total Stockholder Equity Most Recent Quarter | 827,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -29,275,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -6.22 |
| Free Cash Flow Past Year | -29,647,000 |
| Free Cash Flow Prior Year | -26,091,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.03 |
| MACD Signal | -0.05 |
| 20-Day Bollinger Lower Band | -0.87 |
| 20-Day Bollinger Middle Band | 0.80 |
| 20-Day Bollinger Upper Band | 2.47 |
| Beta | 0.62 |
| RSI | 29.13 |
| 50-Day SMA | 41.09 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 9/7/2024 12:06:20 AM EST |